What Searle Pharmaceuticals does

The Searle Company Limited is a Pakistan-headquartered, publicly listed (PSX: SEARL) diversified pharmaceutical and healthcare company operating across six business segments: Pharmaceuticals, Biopharmaceuticals, Nutraceuticals, Nutrition, Consumer Products, and Medical Devices & Disposables. Founded in 1888 in the USA and incorporated in Pakistan in 1965 as a subsidiary of G.D. Searle & Co., the company now operates under the IBL Group umbrella with 3,000+ professionals and a portfolio of more than 300 products spanning 17 therapeutic categories including cardiovascular, oncology, neurology, anti-infective, gastrointestinal, endocrinology, and respiratory. Manufacturing is conducted at cGMP-compliant facilities in Karachi (including the Nextar biopharmaceutical plant — Pakistan's first and only USFDA-GMP-compliant integrated biosimilar API facility), Lahore (the country's largest liquid manufacturing facility), and Harzé, Belgium (Searle-Bel nutraceutical joint venture with BRC certification).

Searle generates revenue through prescription and OTC pharmaceutical sales via a domestic field force in Pakistan, international distribution across 18 countries (Southeast Asia, South Asia, GCC, East Africa, Francophone Africa), contract manufacturing for multinationals including AstraZeneca, RB, and ICI Pakistan, consumer brands such as Canderel and Equal sweeteners, and Mead Johnson infant nutrition distribution. The Global Business Division crossed PKR 2.32 billion in export revenue (2019-20) at a 58% CAGR, with Cambodia specifically delivering 85% CAGR, and Searle ranks as the 2nd largest pharmaceutical exporter from Pakistan. Biosimilars (Adalimumab, Rituximab, Denosumab, Filgrastim, Erythropoietin, Enoxaparin) represent a higher-margin growth vector at the Nextar facility, while the Searle Healthcare Division (established September 2020) addresses direct-to-consumer nutrition. The company holds DRAP cGMP, ISO 9001/14001/45001, Philippines GMP, Ivory Coast/Senegal GMP, and BRC certifications, was the only Pakistani pharmaceutical company on Forbes Asia's Best Under a Billion 2020 list, and is led by CEO Mr. Tahir Ahmed following the June 2025 transition from Dr. Syed Nadeem Ahmed (now Executive Director and Senior Advisor).

Name

Searle Pharmaceuticals

Legal name

The Searle Company Limited

Website

https://searlecompany.com

Company type

Public

Founded year

1888

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

The Searle Company Limited is a Pakistan-listed diversified pharmaceutical manufacturer operating across pharmaceuticals, biosimilars, nutraceuticals, nutrition, consumer products, and medical devices, serving 18 countries with 300+ products via its domestic field force, international distribution network, and contract manufacturing for multinationals.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Drugs and Druggists' Sundries Merchant Wholesalers (4242)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Specialty Pharmaceutical Distributors (HLAIAJAB)

akta.pro secondary industries

Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD), Full-Line Pharmaceutical Wholesalers (HLAIAJAA)

Keywords

• Pharmaceutical manufacturing
• Biopharmaceutical products
• Nutraceutical supplements
• Medical devices disposables
• Contract manufacturing services

Headquarters

HQ city

Karachi

HQ country

Pakistan

HQ region

Asia

Offices10 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Products: Sale of prescription and over-the-counter pharmaceutical products across multiple therapeutic categories including cardiovascular, gastrointestinal, neurology, oncology, and anti-infective segments
2. Biopharmaceutical Products: Sale of biosimilar products including monoclonal antibodies, erythropoietin, filgrastim, and other biologics
3. Nutraceutical Products: Sale of nutritional supplements, vitamins, minerals, probiotics, and herbal supplements
4. Consumer Products: Sale of consumer products including sweeteners (Canderel, Equal), nutritional products, and vitamin water
5. Medical Devices & Disposables: Sale of IV administration sets, syringes, anesthesia masks, surgical gloves, ophthalmology products, and renal care products
6. Contract Manufacturing: Contract manufacturing for multinational companies including AstraZeneca, RB, and ICI Pakistan

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

The Searle Company Limited manufactures and markets a diversified pharmaceutical and healthcare portfolio across six segments: prescription pharmaceuticals spanning 17 therapeutic categories, biopharmaceuticals (biosimilars including monoclonal antibodies), nutraceuticals (probiotics, vitamins, minerals), nutrition products (infant formulas, clinical nutrition), consumer products (sweeteners Canderel and Equal, vitamin waters), and medical devices & disposables. The company also provides contract manufacturing services for multinational pharmaceutical companies such as AstraZeneca, RB, and ICI Pakistan from cGMP-compliant facilities in Pakistan and Belgium.

Product overview

The Searle Company Limited operates as a diversified pharmaceutical and healthcare company with six distinct business segments: Pharmaceuticals (covering 17 therapeutic categories including analgesics, anti-infectives, cardiovascular, gastrointestinal, and more), Biopharmaceuticals (monoclonal antibodies, biologics including Adalimumab, Rituximab, Denosumab, and erythropoietin products), Nutraceuticals (probiotics, vitamins, minerals, and herbal supplements), Nutrition (infant formulas under Mead Johnson and proprietary brands, clinical nutrition products), Consumer products (sweeteners including Canderel and Equal, Protiex probiotics, vitamin waters), and Medical Devices & Disposables (IV administration sets, syringes, cannulas, anesthesia/critical care equipment, contact lens solutions, examination and surgical gloves, ophthalmology products). The portfolio includes over 150 pharmaceutical brands, 12+ biopharmaceutical products, 20+ nutraceutical products, and comprehensive medical device offerings across hospital and consumer segments.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharmaceutical Products Prescription and over-the-counter pharmaceutical products spanning 17 therapeutic categories including analgesics and muscle relaxants, anti-infectives, anti-neoplastics, anti-thrombotics, cardiovascular, endocrinology and metabolism, gastrointestinal, gynecology/urology/sex hormones, neuropsychiatry, respiratory, anti-allergy, and pediatrics. Products sold under Searle's own brands (Adronil, Ventek, Hydryllin, Nuberol Forte, Metrozine, Xaraban, Extor, Jentin Met, Peditral, Andrex, Aldomet, Renitec, Cozaar, Zocor, Lomotil, Gravinate, Calan, Co-Olesta, Conifa, Decadron, Defera, D-Votal, Dactovi, Colril, Bilfaxin, etc.) and licensed brands. Target buyers include hospitals, pharmacies, clinics, and healthcare providers, with patients as end consumers.
• Biopharmaceutical Products (Biosimilars) Biosimilar and biologic products including monoclonal antibodies and therapeutic biologics: Actinib, Cizumab, Clotenox, Dalimab (Adalimumab 40mg/0.8ml pre-filled syringe for Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Uveitis, Crohn's Disease, and Ulcerative Colitis), DENOSU (Denosumab 120mg/1.7ml for bone metastases and Giant Cell Tumor of Bone), Enoprin (Enoxaparin pre-filled syringe for DVT prevention), Hemax (Recombinant Human Erythropoietin for anemia in CKD and cancer), Neutromax (Filgrastim 300mcg for low blood neutrophils), Nexfil, NP-poetin (Epoetin Alpha for anemia), Rexeva 60mg (for post-menopausal osteoporosis), and Tuximab (Rituximab for Non-Hodgkin's lymphoma, CLL, Rheumatoid arthritis, Pemphigus vulgaris). Manufactured at USFDA GMP-compliant Nextar facility. Target buyers include hospitals, oncology centers, specialty clinics, and healthcare providers.
• Nutraceutical Products Nutritional supplements, vitamins, minerals, probiotics, herbal remedies, and wellness products. Includes Cranio-D (D-Mannose 500mg + Cranberry 9mg for urinary tract health), Bacipore (Bacillus Clausii ampoule for diarrhea/IBS), Ecotec (probiotic with Lactobacillus acidophilus, Bifidobacterium, Streptococcus thermophilus, Lactobacillus delbrueckii), Combined Clostridium Butyricum & Bifidobacterium Powder (Gutcare), Essential Plus multivitamin, Essential Scarless Cream, Ez-Colic, Hylixia/Hylixia Plus/Hyplar (Pelargonium root extract for respiratory), Imutec, M-Folate, Ostegem Syrup/Tablet, Pregna Essential, Remac/Remac Plus, Uflora, Vigo Essential, Vita-Active, and Vitrum. Manufactured at Searle Healthcare Division in Karachi and Searle-Bel Belgium. Target buyers include health-conscious consumers, pharmacies, and retail outlets.
• Nutrition Products (Infant Formula and Clinical Nutrition) Infant formulas, follow-up nutrition, maternal nutrition, and clinical nutrition products distributed through Searle's partnership with Mead Johnson Nutrition and proprietary brands. Includes Enfagrow A+3, Enfagrow A+4, Enfamama A+, Enfamil A+ Premature, Enfamil A+1, Enfamil A+2, Enfamil AR (anti-reflux), Enfamil O-LAC (lactose-free), NI-Grow+, NI-1, NI-AC, NI-AR, NI-FU, NI-Grow, NI-LF, NI-Mom, Novasource Renal, Nurtugrow, Nurtumama, Nurtumil, Nurtumil-FU, Nurtumil-LF, Oral Impact Powder, Peptamen, Prep-Up Rice, Prep-Up Rice Milk, Prep-Up Wheat Milk, Resource Diabetes, Isocal, Boost Beneprotein. Target buyers include mothers, caregivers, hospitals, and clinical nutrition patients.
• Consumer Products (Sweeteners and Vitamin Waters) Consumer brands including Canderel (stevia-based sweetener), Equal (aspartame-based sweetener), Protiex (probiotic supplement), and Vitamine Water (vitamin-fortified beverage in carbonated and non-carbonated variants). Manufactured at Searle Consumer Plant at Port Qasim, Karachi, with Food Business License from Sindh Food Authority. Target buyers are health-conscious consumers and retail purchasers.
• Medical Devices and Disposables Medical devices and disposables covering ophthalmology, IV administration, anesthesia, surgical, and renal care. Products include Artelac Nightime Gel (carbomer gel for dry eye), Artelac Advanced (hyaluronic acid 0.2% drops), BIOTRUE and Bostan Simplus contact lens solutions, Cationorm ophthalmic emulsifier, Cosopt ophthalmic product, Kariflex Blood Transfusion Set, Karifusion IV Set, MEDECO auto-disable syringes (0.05ml BCG, 0.5ml), MEDECO Inject Insulin syringe, MEDECO IV cannulas (pen type and ported), Medeco Standard Syringe, Medeset IV infusion sets (basic and Y-port), Meditech Anesthesia Masks, Meditech Circuits/Connecters/Filters/Oxygen Therapy, PROTIEX Examination Gloves (powder-free/powdered latex and powder-free nitrile), PROTIEX Surgical Gloves (powder-free and powdered), RENU MultiPlus contact lens solution and rewetting drops, Robust Inhaler, and Searle Blood Tubing Set for Hemodialysis. Target buyers are hospitals, clinics, ophthalmologists, and retail pharmacies.
• Contract Manufacturing Services Contract manufacturing services for multinational pharmaceutical companies across diverse dosage forms, leveraging cGMP, USFDA, DRAP, ISO, and BRC-certified facilities in Pakistan and Belgium. Key clients include AstraZeneca, RB (Reckitt Benckiser), and ICI Pakistan. Includes nutraceutical contract manufacturing via Searle-Bel Belgium joint venture with Belourthe S.A. for European-standard products. Target buyers are multinational pharmaceutical procurement and supply chain organizations.

Quantifiable outcome

• PKR 2.32 billion export revenue with 58% CAGR (2019-20)
• +3 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

13 partnerships are on record, tiered core and minor.

• Belourthe S.A., BelgiumcoreStrategic or Co-development Partner · 14 February 2018Joint venture established February 2018 for nutraceutical manufacturing. Searle-Bel facility in Harzé, Belgium produces nutraceutical products according to European standards certified by British Retail Consortium (BRC).
• Beximco Pharma, BangladeshcoreStrategic or Co-development PartnerPartnership for supply of Remdesivir injection (Bemsivir I.V.) in May 2020 during COVID-19 pandemic. Beximco is USFDA approved first leading company to develop generic Remdesivir.
• AstraZenecacoreStrategic or Co-development PartnerContract manufacturing partner for pharmaceutical products
• RB (Reckitt)coreStrategic or Co-development PartnerContract manufacturing partner
• Grunenthal GmbH, GermanycoreStrategic or Co-development PartnerInternational partner with strong alliance for pharmaceutical products
• 3M (England)coreStrategic or Co-development PartnerInternational alliance for medical products
• SanoficoreStrategic or Co-development PartnerInternational pharmaceutical alliance
• Forest Laboratories UK Limited (formerly Pharmax)coreStrategic or Co-development PartnerInternational pharmaceutical alliance
• Mead Johnson NutritioncoreChannel Partner/ Reseller/ DistributorPartnership for nutrition products distribution - Thailand/Netherlands origin
• NED University of Engineering & TechnologyminorStrategic or Co-development PartnerPartnership for Urban & Infrastructure Development Project. Searle supporting establishment of Rashid Abdulla Research Centre for engineering students.
• Institute of Business Administration (IBA) KarachiminorStrategic or Co-development PartnerMoU signed October 2021 to establish Rashid Abdulla Consumer Neuroscience Lab at IBA School of Business Studies
• Bahauddin Zakariya University, MultanminorStrategic or Co-development PartnerMoU signed October 2020 for research collaboration
• International Center for Chemical and Biological Sciences (ICCBS), University of KarachiminorStrategic or Co-development PartnerResearch grant agreement signed October 2017 to support strengthening of genomics research over five years

Scale indicators14 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Cipla: Indian global pharmaceutical major with leadership in respiratory, anti-retroviral and biosimilar segments; significant emerging-market distribution footprint. Comparable to Searle as a broad-based generics manufacturer competing in many of the same African, South Asian and Southeast Asian markets.
• Aurobindo Pharma: Indian global generics manufacturer with strong presence in Africa, Southeast Asia, and other emerging markets; broad anti-infective, cardiovascular and CNS portfolios. Comparable to Searle on emerging-market generics scale, international distribution network, and contract manufacturing capabilities.
• Dr. Reddy's Laboratories: Indian multinational with global generics, biosimilars (rituximab, bevacizumab), and API manufacturing operations. Comparable to Searle on biosimilar ambitions, emerging-market distribution, and contract manufacturing scale.

Emerging players

• Biocon: Indian biopharmaceutical company with leading biosimilar portfolio (trastuzumab, bevacizumab, adalimumab, insulin analogs) and global emerging-market distribution. Comparable to Searle's Nextar biosimilar strategy and contract manufacturing partnerships with global pharma.

Direct peers

• Highnoon Laboratories: Pakistani pharmaceutical manufacturer with branded generics, OTC, and consumer health products. Comparable to Searle in domestic Pakistan market dynamics, therapeutic breadth, and product portfolio structure.
• CCL Pharmaceuticals: Pakistani pharmaceutical manufacturer with branded generics, nutraceuticals, and consumer health products. Comparable to Searle as a domestic manufacturer with similar therapeutic category mix and growing export footprint.
• Getz Pharma: Pakistan-based pharmaceutical manufacturer with a broad branded generics portfolio across multiple therapeutic areas and growing international presence. Closely comparable to Searle in domestic market positioning, manufacturing scale, and export orientation.
• Sami Pharmaceuticals: Karachi-headquartered pharmaceutical company with branded generics, consumer health, and API manufacturing operations. Comparable to Searle in Pakistan market positioning, therapeutic breadth, and product portfolio structure.
• Hilton Pharma: Pakistan's largest pharmaceutical manufacturer by sales with a diversified branded generics portfolio and cGMP manufacturing facilities. A direct competitor to Searle in domestic therapeutic categories and a benchmark for Pakistan pharma scale.
• Beximco Pharmaceuticals: Bangladeshi pharmaceutical manufacturer with USFDA-approved facilities and active exports across emerging markets in Asia and Africa. Comparable to Searle as a South Asian generics exporter with similar therapeutic breadth and contract manufacturing capability; also a Searle partner for Remdesivir.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/searlesociallyresponsible
• LinkedInlinkedin.com/company/searle-pakistan-limited

Compliance17 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Searle Pharmaceuticals